

HALF YEAR 2022 RESULTS WEBCAST AND CONFERENCE CALL

September 30, 2022

|Vivoryon Therapeutics N.V.

IMPORTANT NOTICE AND DISCLAIMER

This document has been prepared by Vivoryon Therapeutics N.V. (the "Company" or "We") strictly only for discussion purposes. This document does not constitute or form part of any offer or invitation to sell or issue, any offer or inducement or invitation or commitment to purchase or subscribe for, or any solicitation of any offer to purchase or subscribe for, any securities in the Company or any other entity. By reviewing this document, you represent that you are able to receive this document without contravention of any legal or regulatory restrictions applicable to you and will not use this information in relation to any investment decision.

This document and its contents are strictly confidential and may not be reproduced, redistributed, published or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose. Failure to comply with these restrictions may constitute a violation of applicable securities laws. Certain information contained in this document is non-public, proprietary and highly confidential information. Accordingly, by accepting and reading this document, you will be deemed to agree not to disclose, reproduce or otherwise distribute any information contained herein.

Certain information contained in this document has been obtained from published and non-published sources prepared by third parties. While such information is believed to be reliable for the purposes used herein, none of the Company or its affiliates, directors, officers, employees, members, partners, shareholders or agents make any representation or warranty with respect to or assume any responsibility for the accuracy of such information, and such information has not been independently verified by the Company.

Certain statements contained in this document constitute forward-looking statements, estimates, predictions, influences and projections which are subject to risks and uncertainties and may reflect various assumptions, which may or may not prove to be correct. These forward-looking statements include information about possible or assumed future results of the Company's business, financial condition, results of operations, liquidity, plans and objectives. In particular, the words "anticipate," "believe," "could," "expect," "should," "plan," "intend." "estimate" and "potential." or other similar expressions are intended to identify forward-looking statements. Forward-looking statements appear in a number of places in this presentation and include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to of various risk factors and uncertainties including without limitation in relation to: the effectiveness of our main product candidate, and our ability to commercialize it if the regulatory approval is obtained; our ability to explore benefits of combination therapies between our product candidates and other products; our ability to compete and conduct our business in the future; our ability to overcome the challenges posed by the COVID-19 pandemic to the conduct of our business; our ability to expend our limited resources and to obtain funding for our operations necessary to complete further development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approval for our product candidates; the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs. Moreover, we operate in an evolving environment. Thus, new risk factors and uncertainties emerge from time to time and it is not possible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements.

Forward-looking statements speak only as of the date they are made, and we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events or otherwise, except as required by applicable law.




VIVORYON'S APPROACH TO OVERCOMING THE CHALLENGES OF AD DRUG DEVELOPMENT

Oral small molecule inhibitor varoglutamstat targeting multiple hallmarks of AD

QPCT/L AS KEY TARGET IN AD

- High unmet medical need in AD despite recent advances
 - First potentially disease-modifying treatment approved in the U.S. is not broadly available outside clinical study setting
 - Uncertainties around regulatory path to approval for current Abeta-antibody-based approaches
- Varoglutamstat is designed as an alternative to overcome challenges of AD drug development
 - ◆ Phase 2b-stage oral small molecule with unique, dual mode of Gantenerumab action that is truly differentiated from the other approaches in clinical development
 - Prevents formation of toxic Abeta species upstream of other approaches, thereby also targeting tau pathology, neuroinflammation and synaptic impairment
 - ◆ Development strategy rooted in promising Ph 1 and Ph 2a results (well-tolerated, statistically significant changes in working memory after only 3 months of treatment)
 - Protected by strong patent estate

VAROGLUTAMSTAT TARGETS UPSTREAM PATHOGENESIS



CORPORATE DEVELOPMENT HIGHLIGHTS

- Financing events to support ongoing clinical development of varoglutamstat
 - ◆ April 2022: EUR 21 million raised in private placement; capital raise supported by a number of high-quality institutional investors from Europe and the U.S. as well as members of Vivoryon's Executive and Non-Executive Boards
 - ◆ September 2022: EUR 15 million raised in private placement with option to place an additional EUR 15 million; private placement supported by longstanding investor Claus Christiansen and our new investor KKR Dawn Aggregator, a platform controlled by affiliates of KKR, a leading global investment firm (post-period)
- Non-Executive Board expanded and diversified by appointment of Dr. Claudia Riedl and Samir Shah,
 MD; all existing members re-appointed by AGM (post-period)
- ◆ Clinical Trial Application submitted by partner Simcere for the development of varoglutamstat in Greater China approved by China's Center for Drug Evaluation (CDE); preparations ongoing for Phase 1 study and subsequent Phase 2 study



CLINICAL PORTFOLIO HIGHLIGHTS

- ◆ VIVIAD European Ph 2b study of varoglutamstat completed parallel group, dose-finding part, and independent Data Safety Monitoring Board (DSMB) selected highest dose investigated, 600 mg twice daily (BID), as final dose in second part of study (post-period)
- ◆ Detailed safety data from VIVIAD study, presented at Alzheimer's Association International Conference (AAIC) 2022 in San Diego, show that varoglutamstat was well tolerated while retaining a similar level of target inhibition compared to 800 mg administered in prior Phase 2a study (postperiod); study on track for final data readout in the second half of 2023 with currently 22 active sites in 5 countries open
- ◆ Preclinical data presented at AAIC 2022 for N3pE amyloid-targeting molecules underscore unique potential of Vivoryon's strategy in mono- and combination therapy settings in AD (post-period)
- ◆ VIVA-MIND U.S. Ph 2a/b study of varoglutamstat actively enrolling patients, currently 14 sites open, on track for interim futility analysis planned for H1/2023

VAROGLUTAMSTAT CLINICAL MILESTONES

2022/2023 Outlook





Phase 2b study in 250 patients with MCI/mild AD



Endpoints: safety, attention/working memory, NTB, biomarkers

- ◆ 22 sites in 5 countries active
 - No pandemic-related delays
- ◆ Parallel group, dose-finding part completed, study continues with DSMB recommended maximum dose of 600 mg BID or placebo
- ◆ Dose of 600 mg BID know to result in 87% target engagement
- ◆ Discontinuation rate reduced from 33% in SAPHIR to 1.1% in VIVIAD
- All patients now randomized 1:1 (placebo/600 mg)

H2/2023 final readout







Phase 2a/b study in 414 patients with early AD




Endpoints: safety, ABC scores/ cognition & EEG , CDR-SB, biomarkers



AD©S

◆ Run by ADCS, supported by NIH grant





◆ FDA Fast Track designation



- ◆ Ph 2a part ongoing with 14 active sites
 - ◆ Randomizing and treating patients despite pandemic and weather-related challenges in the U.S.
 - ◆ On track for interim futility analysis

H1/2023 STAGE GATE DECISION safety/efficacy, transition to Ph 2b





- Clinical Trial Application approved in China
- Preparations ongoing for Phase 1 study and subsequent Phase 2 study

Several key milestones upcoming; overall data set intended to support clear path to approval



CLINICAL DEVELOPMENT STRATEGY

Clear Path To Potential Regulatory Approval Extensive Phase 1 and Phase 2 trials





Preclinical research

In vitro and in vivo studies

COMPLETED

- QPCT inhibition improves cognitive parameters in AD mouse models
- ◆ QPCT is essential for N3pE amyloid and pE-CCL2 formation in vivo



Phase 1

in 205 healthy volunteers

COMPLETED

◆ Varoglutamstat is welltolerated - no DLT at 800mg twice daily or up to 3.6g once daily

Phase 1

Assessment of safety and tolerability

IN PREPARATION



Phase 2a SAPHIR

Assessment of safety and tolerability in 120 patients with early AD

COMPLETED

- Statistically significant changes from baseline in working memory after only 3 months of treatment (as measured by CogState)
- ♦ High target occupancy detected at doses of 150 mg BID and above

Phase 2b VIVIAD

Assessment of safety, tolerability and efficacy in 250 Patients MCI and mild AD

Final readout H2/2023

- Endpoints: safety, attention/working memory, NTB, biomarkers
- Parallel group, dose-finding part completed. Study continues with DSMB recommended maximum dose of 600 mg BID or placebo

Phase 2a/b VIVA-MIND

Assessment of efficacy and safety in 414 patients with early AD

Stage-gate to Ph2b H1/2023

Endpoints: safety, attention/working memory, CDR-SB, biomarkers

Pivotal study or accelerated approval

- FDA Fast Track designation granted in 2021
- ◆ Two possible scenarios for late-stage development
 - Application for accelerated approval (based on consistent/ positive data of Phase 2b studies)
 - Phase 3 clinical development





CONDENSED STATEMENT OF PROFIT AND LOSS

In €k	June 30, 2022	June 30, 2021
Research and development expenses	(11,067)	(9,456)
General and administrative expenses	(2,311)	(2,337)
Operating loss	(13,378)	(11,788)
Finance result	844	117
Income taxes	(89)	0
Net loss for period	(12,583)	(11,671)
Loss per share (basic and diluted) (in EUR)	(0.60)	(0.58)



KEY FINANCIAL FIGURES

In €k	June 30, 2022	December 31, 2021
Cash and cash equivalents	24,383	14,661
Total assets	31,743	24,520
Total equity	25,237	16,557
Shares (number)	22,050,482	20,050,482
In €kh	lune 30 2022	lune 30 2021

In €kh	June 30, 2022	June 30, 2021
Cash flows used in operating activities	(10,237)	(6,072)
Cash flows used in investing activities	(2)	(24)
Cash flows from financing activities	19,581	(513)
Cash and cash equivalents at the end of period	24,383	19,832



